Pharmacodynamics
Progesterone binds and activates its nuclear receptor, PR, which plays an important role in signaling stimuli that maintain the endometrium during its preparation for pregnancy. The progesterone receptor is a member of the ligand-dependent transcription factor family of the nuclear/steroidal hormone receptor, which is expressed primarily in female reproductive tissue as well as in the central nervous system. As a result of its binding to the steroid hormone progesterone associated with it, the progesterone receptor modulates the expression of genes that regulate the development, differentiation and proliferation of target tissues. In humans, PR is highly expressed in stromal cells (connective tissue cells) during the secretory phase and during pregnancy.
Progesterone can prevent pregnancy by altering the consistency of cervical mucus so that it is unfavorable for sperm penetration and by inhibiting follicle-stimulating hormone (FSH), which normally causes ovulation. When used properly, the first-year failure rate for oral contraceptives with progestin alone is about 0.5%. However, the typical failure rate is estimated to be about 5% due to delayed or missed pills.
Pharmacokinetics
Progesterone is present 96%-99% bound to serum proteins, mainly serum albumin (50%-54%) and transcortin (43%-48%). Progesterone is metabolized mainly by the liver. After oral administration, the major plasma metabolites found are 20 a-hydroxy-Δ4 a-prenolone and 5 a-dihydroprogesterone. Progesterone metabolites are excreted mainly by the kidneys.
Interactions
Since progesterone is a naturally occurring hormone, interactions are not expected.